近日,制药头部辉瑞做出一项重大决策,宣布停止 B 型血友病基因疗法 Beqvez 的研发和商业化进程。值得一提的是Beqvez 在 2024 年 4 月才刚刚获得 FDA 批准上市,定价高达 350 万美元,但是一年时间过去,辉瑞便决定终止了该药物的开发和商业化。资料显示,Beqvez是一种基于腺相关病毒(AAV)载体的基因替代疗法,旨在通过一次性治疗解决B型血友病患者的长期出血问题。B型血友病是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.